Craneware revenues up on US healthcare cost pressures
UK-listed but US-focused healthcare software provider Craneware is benefiting from the cost pressures on American hospitals.
UK-listed but US-focused healthcare software provider Craneware is benefiting from the cost pressures on American hospitals.
The company, which provides monitoring and automated revenue systems, has reported revenues of $41.1m in the 12 months to the end of June, a rise of 8% on the prior year.
Adjusted profits before tax came in at $10.8m, a 16% gain on the previous year, while the total dividend for the year has been announced at 10.5p per share, versus 8.8p in 2011.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Craneware's Chief Executive, Keith Neilson, said of the results: "Added pressures on US hospitals have led to an increased sales and opportunity pipeline for our products as we move into the current financial year.
"In this turbulent, demanding environment, hospitals need financial accuracy, visibility and shared accountability to survive. Fiscal and regulatory drivers are expected to increase in the year ahead as they push for greater transparency and accuracy, and although this creates a challenging ever-evolving marketplace, it ultimately increases the opportunities for Craneware's solutions."
The market was impressed with the numbers: the stock was up 7.6% at 10:08.
BS
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Trump wants to colonise Mars – will it happen?
Donald Trump wants to plant the US flag on Mars. Could humans really live there?
By Simon Wilson
-
Klarna postpones US IPO as Trump's tariffs rattle markets
Buy-now-pay-later lender Klarna has postponed its US initial public offering owing to the market turbulence. It is not alone, says Matthew Partridge
By Dr Matthew Partridge